FDA'ｓ Advisory Meetings（７月19日）
公開日時 2010/07/22 04:00
| Class-wide Risk Evaluation and Mitigation Strategy for opioid drugs |
Anesthetic and Life Support Drugs and Drug Safety and Risk Management |
July 22-23 |
| Blood safety and availability, emerging arboviruses, emerging infectious diseases, the Q fever epidemic in the Netherlands, xenotropic murine leukemia virus-related virus, babesia infections |
Blood Products |
26-Jul |
| Blood donor hemoglobin/hematocrit standards, iron status and interdonation interval |
Blood Products |
27-Jul |
| AstraZeneca's ticagrelor for acute coronary syndrome |
Cardiovascular and Renal Drugs |
28-Jul |
| Pfizer's Revatio (sildenafil) for pediatric pulmonary arterial hypertension |
Cardiovascular and Renal Drugs |
29-Jul |
| Valeant Pharmaceuticals North America's Potiga (ezogabine) for adjunctive therapy in patients with partial-onset seizures |
Peripheral and Central Nervous System Drugs |
Aug. 11 |
| Interim report on CDER's pharmacovigilance program; JANUS, the FDA-supported data standard for comparative effectiveness research; FDA's nanotechnology research program |
Science Board |
Aug. 16 |
| Lilly's Cymbalta (duloxetine HCl) for chronic pain |
Anesthetic and Life Support Drugs |
Aug. 19 |
| Jazz Pharmaceuticals' sodium oxybate for fibromyalgia in patients age 18 and up |
Arthritis and Drug Safety and Risk Management |
Aug. 20 |
| Cerexa's ceftaroline fosamil for community-acquired bacterial pneumonia and complicated skin and skin structure infections |
Anti-infective Drugs |
Sept. 7 |
| Abuse potential of the cough suppressant dextromethorphan and a Drug Enforcement Administration request for a scheduling recommendation for the drug |
Drug Safety and Risk Management |
Sept. 14 |
（The Pink Sheet ７月19日号より） FDAと米国製薬企業の情報満載 “The Pink Sheet”はこちらから